These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31065295)

  • 1. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.
    Ho CM; Chen HL; Hu RH; Lee PH
    Ther Adv Med Oncol; 2019; 11():1758835919843463. PubMed ID: 31065295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
    Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
    Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
    Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.
    Luo Y; Teng F; Fu H; Ding GS
    World J Gastrointest Oncol; 2022 Jan; 14(1):163-180. PubMed ID: 35116109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab.
    Amjad W; Kotiah S; Gupta A; Morris M; Liu L; Thuluvath PJ
    J Clin Exp Hepatol; 2020; 10(2):185-187. PubMed ID: 32189935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of checkpoint inhibitors in liver transplant recipients.
    Munker S; De Toni EN
    United European Gastroenterol J; 2018 Aug; 6(7):970-973. PubMed ID: 30228883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.
    Aguirre LE; Guzman ME; Lopes G; Hurley J
    Oncologist; 2019 Mar; 24(3):394-401. PubMed ID: 30413665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.
    Macek Jilkova Z; Aspord C; Decaens T
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31615069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
    Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
    Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.
    Chae YK; Galvez C; Anker JF; Iams WT; Bhave M
    Cancer Treat Rev; 2018 Feb; 63():116-121. PubMed ID: 29276997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors.
    Moris D; Rahnemai-Azar AA; Zhang X; Ntanasis-Stathopoulos I; Tsilimigras DI; Chakedis J; Argyrou C; Fung JJ; Pawlik TM
    Surg Oncol; 2017 Dec; 26(4):423-430. PubMed ID: 29113661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
    Owonikoko TK; Kumar M; Yang S; Kamphorst AO; Pillai RN; Akondy R; Nautiyal V; Chatwal MS; Book WM; Sahu A; Sica GL; Ahmed R; Ramalingam SS
    Cancer Immunol Immunother; 2017 Jan; 66(1):45-50. PubMed ID: 27771741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.
    Shi XL; Mancham S; Hansen BE; de Knegt RJ; de Jonge J; van der Laan LJ; Rivadeneira F; Metselaar HJ; Kwekkeboom J
    J Hepatol; 2016 Jun; 64(6):1274-82. PubMed ID: 26941095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.